Abstract 165P
Background
The role of T-cell immunoreceptor with Ig and ITIM domains (TIGIT) as an immune checkpoint has garnered significant interest in oncology, particularly in the context of non-small cell lung cancer (NSCLC). TIGIT inhibition represents a promising therapeutic strategy, potentially enhancing anti-tumor immunity. This meta-analysis aims to evaluate the clinical efficacy of TIGIT inhibitors in NSCLC and to explore the correlation between TIGIT expression and relevant biomarkers.
Methods
A comprehensive literature search was conducted in databases such as PubMed, Scopus, and clinical trial registries up to June 2024. Studies were included if they reported clinical outcomes of TIGIT inhibitors in NSCLC patients. Data extraction focused on progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and safety profiles. Biomarker correlation analysis included TIGIT expression levels, PD-L1 status, and other immune-related markers. Statistical analysis involved pooled hazard ratios (HRs) for PFS and OS, and odds ratios (ORs) for ORR, with 95% confidence intervals (CIs).
Results
A total of 12 studies encompassing 1,750 patients were included. TIGIT inhibition showed a significant improvement in PFS (HR 0.73, 95% CI 0.61-0.87) and OS (HR 0.78, 95% CI 0.66-0.92) compared to standard treatments. The ORR was notably higher in the TIGIT inhibitor group (OR 1.45, 95% CI 1.21-1.73). Biomarker analysis revealed a positive correlation between high TIGIT expression and enhanced response rates. Additionally, patients with concurrent high PD-L1 expression demonstrated a synergistic benefit from TIGIT inhibition. The safety profile of TIGIT inhibitors was manageable, with no unexpected adverse events.
Conclusions
TIGIT inhibition offers a significant therapeutic benefit in NSCLC, improving survival outcomes and response rates. The correlation between TIGIT expression and clinical efficacy underscores the potential for biomarker-driven patient selection. These findings support further investigation and development of TIGIT inhibitors as a component of NSCLC treatment regimens.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
Resources:
Abstract
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
Resources:
Abstract
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
Resources:
Abstract
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
Resources:
Abstract
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
Resources:
Abstract
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
Resources:
Abstract
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
Resources:
Abstract
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session
Resources:
Abstract